Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
November 26th 2021
Results of Annual General Meeting
November 26th 2021
Immutep AGM 2021 - CEO's presentation
November 26th 2021
Immutep AGM 2021 - Chairman's Address
November 19th 2021
Phase II TACTI-002 trial recruitment successfully completed
November 17th 2021
Immutep Global Webcast Slides to Discuss Clinical Results
November 15th 2021
Immutep announces publication of SITC 2021 posters
November 15th 2021
Chinese patent Granted for Efti with PD-1 Pathway Inhibitors
November 10th 2021
Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer
November 10th 2021
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
November 2nd 2021
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent
October 29th 2021
Immutep receives EMA scientific advice in Phase 3 in MBC
October 28th 2021
Immutep Quarterly Activities Report & Appendix 4C
October 12th 2021
2021 Annual General Meeting and Key Dates
October 4th 2021
Immutep to present Phase II TACTI-002 data at SITC 2021
September 29th 2021
Immutep Receives A$3.4 million R&D French Tax Incentive
September 28th 2021
Immutep to Present at Healthcare Investor Conferences
September 22nd 2021
Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
September 1st 2021
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
June 21st 2021
Immutep secures commitments for A$60 million through a two-tranche institutional placement to expand its clinical development and manufacturing program into late-stage settings
June 21st 2021
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
June 8th 2021
Immutep Reveals a New anti-LAG-3 Research Program
June 4th 2021
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
June 4th 2021
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
June 2nd 2021
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor
June 1st 2021
Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
May 26th 2021
Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
May 25th 2021
Immutep to Present at the Jefferies Virtual Healthcare Conference
May 7th 2021
Immutep Operational Update
April 29th 2021
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
April 19th 2021
Immutep Quarterly Activities Report & Appendix 4C
April 16th 2021
Immutep Receives A$1,155,055 R&D Tax Incentive
April 8th 2021
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
April 7th 2021
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
March 16th 2021
Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
March 9th 2021
Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
March 5th 2021
Immutep Expands Part B of TACTI-002 Collaboration Trial
January 27th 2021
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
January 22nd 2021
Immutep Quarterly Activities Report & Appendix 4C
January 22nd 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
January 7th 2021
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies. To learn more about cookies view ourPrivacy policy
